MNPR vs GILD: Which Stock is Better?
Side-by-side comparison of Monopar Therapeutics and Gilead Sciences Inc in 2026
MNPR
Monopar Therapeutics
$70.32
GILD
Gilead Sciences Inc
$124.14
Key Metrics Comparison
| Metric | MNPR | GILD | Winner |
|---|---|---|---|
| Market Cap | $469.92M | $154.99B | GILD |
| P/E Ratio | N/A | 19.34 | GILD |
| EPS (TTM) | $N/A | $6.46 | GILD |
| Revenue Growth | 0.0% | 0.0% | GILD |
| Gross Margin | 0.0% | 78.7% | GILD |
Analyze MNPR
Full quant analysis
Analyze GILD
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is MNPR or GILD a better investment?
Comparing MNPR and GILD: Monopar Therapeutics has a market cap of $469.92M while Gilead Sciences Inc has $154.99B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between MNPR and GILD?
MNPR (Monopar Therapeutics) and GILD (Gilead Sciences Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: MNPR or GILD?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: MNPR or GILD?
GILD has higher revenue growth at 0.0% vs 0.0% for MNPR.
Which company is more profitable: MNPR or GILD?
Gilead Sciences Inc (GILD) has higher gross margins at 78.7% compared to 0.0% for MNPR.
Which is the larger company: MNPR or GILD?
Gilead Sciences Inc (GILD) is larger with a market cap of $154.99B compared to $469.92M for MNPR.
Should I buy MNPR or GILD in 2026?
Both MNPR and GILD have investment merit. MNPR trades at $70.32 while GILD trades at $124.14. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between MNPR and GILD stock?
Key differences: Market Cap ($469.92M vs $154.99B), P/E Ratio (N/A vs 19.3x), Revenue Growth (0.0% vs 0.0%), Gross Margin (0.0% vs 78.7%).